Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 3:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HuLuc63 Clear all

Conditions: Multiple Myeloma
Interventions: Cevostamab, Pomalidomide, Dexamethasone, Daratumumab, Elotuzumab, Carfilzomib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 10
States / cities: Duarte, California • Irvine, California • New Haven, Connecticut + 7 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 22
States / cities: Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, Dexamethasone, Bortezomib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Dexamethasone, Lenalidomide, Bortezomib, Pomalidomide, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 14
States / cities: Tucson, Arizona • Bakersfield, California • Fountain Valley, California + 11 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Carfilzomib, Lenalidomide, Dexamethasone; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 3
States / cities: Chicago, Illinois • Evanston, Illinois • Ann Arbor, Michigan

Conditions: Multiple Myeloma
Interventions: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 100
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

Conditions: Multiple Myeloma
Interventions: bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab; Biological · Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 386 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 36
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 26 more

Conditions: Recurrent Multiple Myeloma
Interventions: Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Elotuzumab, Iberdomide, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Biological · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803; Drug · Procedure · Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma in Relapse
Interventions: Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 2
States / cities: Denver, Colorado • St Louis, Missouri

Conditions: IgG4 Related Disease, IgG4-RD
Interventions: elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 12
States / cities: Atlanta, Georgia • Chicago, Illinois • Indianapolis, Indiana + 8 more

Conditions: Multiple Myeloma
Interventions: Selinexor, Dexamethasone, Lenalidomide, Pomalidomide, Bortezomib, Daratumumab, Carfilzomib, Ixazomib, Elotuzumab, Clarithromycin, Belantamab Mafodotin, Mezigdomide; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 16
States / cities: Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 10 more

Conditions: Relapsed Refractory Multiple Myeloma (RRMM)
Interventions: Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2033
U.S. locations: 10
States / cities: Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more

Conditions: Lymphoma, Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Dexamethasone (Oral), Dexamethasone (IV), Elotuzumab (BMS-901608; HuLuc63); Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 646 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 63
States / cities: Muscle Shoals, Alabama • Tucson, Arizona • Berkeley, California + 53 more

Conditions: Multiple Myeloma
Interventions: Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 72
States / cities: Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dexamethasone, Echocardiography, Elotuzumab, Magnetic Resonance Imaging, Mezigdomide, X-Ray Imaging; Procedure · Drug · Biological
Lead sponsor: Abdullah Khan; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Newly Diagnosed, Previously Untreated Multiple Myeloma
Interventions: Lenalidomide, Dexamethasone, Elotuzumab; Drug · Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 9
States / cities: San Francisco, California • Hollywood, Florida • Peoria, Illinois + 6 more

Conditions: Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Elotuzumab, Iberdomide, Dexamethasone; Drug
Lead sponsor: Omar Nadeem, MD; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Recurrent Primary Amyloidosis
Interventions: Cyclophosphamide, Dexamethasone, Elotuzumab, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study; Drug · Biological · Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 5
States / cities: Duarte, California • Denver, Colorado • Atlanta, Georgia + 2 more

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions: Elotuzumab, Questionnaire Administration; Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Mantle-Cell Lymphoma, Follicular Lymphoma, Indolent B Cell Lymphoma, Primary Mediastinal Lymphoma, Lymphoplasmacytic Lymphoma
Interventions: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells; Biological
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Search by objective public record fields.

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Study of Initial Treatment With Elotuzumab, Carfilzomib, Lenalidomide and Dexamethasone in Multiple Myeloma

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

An Investigational Immuno-therapy Trial of Pomalidomide and Low-dose Dexamethasone With or Without Elotuzumab to Treat Refractory and Relapsed and Refractory Multiple Myeloma (ELOQUENT-3)

Selinexor and Backbone Treatments of Multiple Myeloma Patients

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

ELEVATE-MM: Elotuzumab, Iberdomide and Dexamethasone Post Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL